Theoretical Vaccine Effectiveness for Novavax Unacceptably Low
Dr. Peter A. McCullough, MPH
If it came to forced COVID-19 vaccination against human will, I would recommend Novavax because it contains only a 5 mcg dose of the potentially lethal Spike protein and contains no genetic material. The growing number of fatal side effects associated with mRNA vaccines, combined with recent news of SV-40 cDNA contamination, has resulted in record low rates of booster uptake, currently at 1.3% of unwary Americans.
Mateo-Urdiales reported on 20,903 people who received the Novavax two-shot primary series. Theoretical vaccine efficacy was startlingly low:
“Adjusted estimated vaccine effectiveness against notified SARS-CoV infections in those who received partial vaccination (15 days after the first dose to 14 days after the second dose) was 23% (95% CI, 13%-33%), increasing to 31% (95% CI, 22%-39%) after full vaccination.” The estimated vaccine effectiveness against symptomatic COVID-19 was higher, with an estimate of 31% (95% CI, 16%-44%) in those who were partially vaccinated and 50% (95% CI, 40%-58%) in those who were fully vaccinated.”
In my clinical practice, a vaccine that cannot safely provide at least 50% protection for a year is not viable. Unfortunately, Novavax fell short of both of these goals. Only 26 infections resulted in hospitalization during the study period, with low-risk Omicron and likely substantial natural immunity by Fall 2022; 1 occurred during the reference period, 7 during partial vaccination, and 18 after full vaccination. There were no reported deaths.
A. Mateo-Urdiales, C. Sacco, D. Petrone, et al. Estimated Effectiveness of a Primary Cycle of NVX-CoV2373 Protein Recombinant Vaccine Against COVID-19. JAMA. 2023;6(10):e2336854. doi:10.1001/jamanetworkopen.2023.36854.
In conclusion, Novavax is likely the safest of the COVID-19 vaccines because it does not employ genetic technology. Unfortunately, it is ineffective against Omicron and cannot be recommended for any health benefits.
Please consider becoming a paying or founding member of Courageous Discourse so that we can continue to bring you the truth.
Dr. Peter McCullough and John Leake’s Courageous DiscourseTM is a reader-supported publication. Consider becoming a free or paid subscriber to receive new posts and support my work.
Dr. Peter A. McCullough, MPH
McCullough Foundation President
www.mcculloughfnd.org
Mateo-Urdiales A, Sacco C, Petrone D, et al. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19. JAMA Netw Open. 2023;6(10):e2336854. doi:10.1001/jamanetworkopen.2023.36854
